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Coronary artery disease (CAD) 11 is the leading cause of death in developed countries like the United States (1 ). Algorithms for risk assessment in patients with CAD include several cardiovascular risk factors or a combination thereof (2 ). There is substantial interest in identifying new biomarkers that might help to better identify patients at increased risk for cardiovascular events who could be targeted for preventive measures. Dimethylarginines have been known to biochemists for decades (3 ). In the past 15 years, scientists mainly focused on asymmetrical dimethylarginine (ADMA), the most potent endogenous nitric oxide (NO) synthase inhibitor. ADMA correlates with traditional and nontraditional cardiovascular risk factors (for a review, see Cooke (4 )) and predicts cardiovascular events and death in different patient populations (5-7 ). However, little attention has been paid to the structural isomer of ADMA, symmetrical dimethylarginine (SDMA). Kakimoto and Akazawa (3 ) showed that both ADMA and SDMA are excreted in the urine, but experimental evidence indicated that SDMA, in contrast to ADMA, is almost completely eliminated by renal excretion (8 ). A metaanalysis of 18 studies convincingly showed that SDMA correlates tightly with the glomerular filtration rate (GFR) in humans (9 ). The same holds true for several animal species (10 ). In addition to being an excellent marker of renal function, SDMA may indirectly interfere with NO synthesis, suggesting a role for cardiovascular diseases (11 ). In this context, recently published results showed that SDMA is of clinical significance as an independent cardiovascular risk factor (12-16 ). In high-risk patients with coronary events as the leading cause of death, however, long-term follow-up data from a large, well-characterized cohort are still missing.
We aimed to evaluate the correlation of SDMA concentrations with renal function, cardiovascular risk factors, and mortality in a large cohort of 3229 patients referred for coronary angiography. In the same study cohort, we previously demonstrated that ADMA is a significant risk factor for mortality after a median follow-up time of 5.45 years (7 ). In our present analyses, with a median follow-up time of 7.7 years, we particularly aimed to elucidate whether SDMA and ADMA differ in their association with cardiovascular risk in patients with coronary heart disease and normal or slightly impaired renal function.
Methods

STUDY DESIGN AND PARTICIPANTS
We studied participants of the Ludwigshafen Risk and Cardiovascular Health (LURIC) study (17 ) . Inclusion criteria were German ancestry, clinical stability except for acute coronary syndromes, and availability of a coronary angiogram. The indications for coronary angiography in individuals in clinically stable condition were chest pain and/or noninvasive test results consistent with myocardial ischemia. We excluded individuals suffering from acute illness other than acute coronary syndromes, chronic noncardiac diseases, or malignancy within the 5 past years and those unable to understand the purpose of the study. Hence patients with clinical evidence for chronic kidney disease were excluded. The study was approved by the ethics committee of the Medical Association of Rheinland-Pfalz (Ärztekammer Rheinland-Pfalz). We obtained informed written consent from all participants.
We assessed CAD by angiography and estimated maximum luminal narrowing by visual analysis. Clinically relevant CAD was defined as the occurrence of Ն1 stenosis of Ն20% in Ն1 of 15 coronary segments.
Individuals with stenoses Ͻ20% were considered not to have CAD. The definition for CAD with a stenosis Ն20% is rather conservative compared with more common definitions such as Ն50% or Ն75%. Use of the Ն20% definition is based on the consideration to identify completely CAD-free patients in whom the calculated quartiles for ADMA and SDMA concentrations may resemble those ranges obtained in a coronary healthy control group. Results for quartile ranges of such a subpopulation might be more comparable to other cohorts without an indication for coronary angiography (as in the LURIC study). The diagnostic criteria of heart failure have been described in the baseline LURIC article (17 ) . In detail, the diagnosis was based on the combined presence of symptoms of dyspnea on exertion and impaired left ventricular function assessed by echocardiography and/or ventricular angiography. Semiquantitatively graded left ventricular function assessed by contrast ventriculography was available in 3194 patients of the LURIC study and correlated significantly with N-terminal pro-B-type natriuretic peptide (NT-proBNP) (r ϭ 0.3; P Ͻ 0.001) and with the calculated ejection fraction (r ϭ 0.8; P Ͻ 0.001), which was available in 1360 study participants.
Diabetes mellitus was diagnosed if plasma glucose was Ͼ1.25 g/L in the fasting state or Ͼ2.00 g/L 2 h after an oral glucose load (18 ) or if individuals were receiving antidiabetic treatment. Hypertension was diagnosed if the systolic and/or diastolic blood pressure exceeded 140 and/or 90 mmHg or if there was a history of hypertension and use of antihypertensive drugs. Women were categorized into pre-, peri-, or postmenopausal according to menstrual bleeding history and the concentrations of follicle-stimulating hormone (17 ) .
LABORATORY PROCEDURES
Blood was drawn in the fasting state before coronary angiography. Standard laboratory methods have been outlined in detail (17 ) . We measured ADMA and SDMA in frozen serum (Ϫ80°C) with the reversedphase HPLC method (19 ) , with slight modifications (20 ) . Within-day CVs for SDMA were 4.6% (0.60 mol/L) and 1.9% (1.0 mol/L), and between-day CVs were 9.8% (0.60 mol/L) and 6.1% (1.0 mol/L). Within-day CVs for ADMA were 3.1% (0.62 mol/L) and 1.0% (2.0 mol/L), and between-day CVs were 9% (0.62 mol/L) and 1.5% (2.0 mol/L). Fibrinogen was measured by use of the Clauss method (Dade Behring). We used immunonephelometry for measurement of C-reactive protein (CRP) (N High Sensitivity CRP; Dade Behring) and cystatin C, the latter being a sensitive parameter to determine GFR (21, 22 ) . We measured NT-proBNP, a marker of ventricular dysfunction and cardiovascular risk (23 ) , by electrochemiluminescence on an Elecsys 2010 (Roche Diag-nostics). We calculated estimated GFR (eGFR) with the Chronic Kidney Disease Epidemiology Collaboration equation (24 ) .
FOLLOW-UP
During follow-up, information on vital status was obtained from local registries. Death certificates as well as medical records of local hospitals and autopsy data were reviewed to classify causes of death. Deceased patients were classified according to whether they died from cardiovascular or noncardiovascular causes. Cardiovascular deaths included sudden cardiac death, fatal myocardial infarction, death due to congestive heart failure, death immediately after intervention to treat CAD, fatal stroke, and other deaths due to cardiac causes. Three experienced clinicians who were blinded to the baseline characteristics of the study participants independently classified the causes of death. In cases of disagreement or uncertainty concerning the coding of a specific cause of death, classification was based on the majority opinion.
STATISTICAL ANALYSIS
Baseline characteristics are presented according to ADMA and SDMA quartiles, which were formed according to the concentrations observed in patients without CAD. Comparisons across these quartiles were done by 2 test with P for linear test for proportions and by ANOVA with P for linear trend for continuous variables. For these analyses, concentrations of triglycerides, CRP, NT-proBNP, and homocysteine were logarithmically transformed to reduce skewness. We used linear regression analyses to explore associations of ADMA and SDMA with markers of kidney function (eGFR, cystatin C), parameters of myocardial dysfunction [NT-proBNP, New York Heart Association (NYHA) class], and others (albumin, hemoglobin, homocysteine, fibrinogen), adjusted for common cardiovascular risk factors (age, sex, body mass index, triglycerides, LDL and HDL cholesterol, CRP, smoking status, diabetes mellitus, hypertension). We used Cox proportional hazards models to compare the risk of all-cause and cardiovascular mortality between the ADMA and SDMA quartiles using the first ADMA and SDMA quartile as the reference. We calculated hazard ratios (HRs) and 95% CIs, which were adjusted for potential confounders as indicated. All statistical tests were 2-sided, and a P value Ͻ0.05 was considered significant. The analyses were performed using SPSS 15.0 statistical package (SPSS Inc.).
Results
ADMA and SDMA concentrations were available in 3229 study participants (97.3% of the entire study cohort). Baseline clinical and laboratory characteristics according to ADMA and SDMA quartiles are shown in Table 1 .
In linear regression analyses including common cardiovascular risk factors as covariates, SDMA concentrations were significantly associated with cystatin C (␤ coefficient 0.715), eGFR (Ϫ0.687), NT-proBNP (0.321), NYHA class (Ϫ0.095), albumin (Ϫ0.087), hemoglobin (Ϫ0.112), homocysteine (0.331), ADMA (0.487), and fibrinogen (0.083) (all P values Յ0.001).
The same analyses with ADMA concentrations showed lower ␤ coefficients compared with SDMA, but associations remained statistically significant with the exception of fibrinogen. In detail we obtained the following results with ADMA concentrations: cystatin C (␤ coefficient 0.414), eGFR (Ϫ0.197), NT-proBNP (0.163), NYHA class (Ϫ0.083), albumin (Ϫ0.094), hemoglobin (0.019), and homocysteine (0.169) (all P values Ͻ0.001). ADMA in contrast to SDMA showed a significant relation to arginine, with a ␤ coefficient of 0.278 (P Ͻ 0.001).
In addition, we performed multivariate linear regression analyses using forward selection methods. We thereby included all variables that showed a significant association with ADMA and SDMA in the previous analyses except eGFR, which was excluded owing to collinearity with cystatin C. In the final model of SDMA, predictors were cystatin C Ͼ ADMA Ͼ NTproBNP Ͼ homocysteine Ͼ CRP Ͼ hemoglobin, with an overall R 2 of 0.58. The order of ADMA predictors was SDMA Ͼ arginine Ͼ cystatin C Ͼ albumin Ͼ hemoglobin Ͼ CRP Ͼ NYHA. The overall R 2 for ADMA was 0.35, suggesting that 35% of the variation of ADMA concentrations was explained by the selected covariates. In contrast, for SDMA, Ͼ50% was explained by the described variables.
Our prospective analyses included a median follow-up time of 7.7 years, during which 749 patients died (22.5% of the study population). We recorded 469 deaths (14.1%) due to cardiovascular causes. Eighteen people were lost during follow-up, and for 24 deceased individuals we did not obtain sufficient data to classify cause of death. These latter individuals were included in the analyses for all-cause mortality but were excluded from analyses for cardiovascular mortality.
For SDMA quartiles, we observed a J-shaped characteristic for the association with total as well as cardiovascular mortality. After adjustments for cardiovascular risk factors, the HRs (95% CIs) in the second, third, and fourth quartiles compared to patients in the lowest SDMA quartile were 0.77 (0.60 -0.99), 0.99 (0.78 -1.25), and 1.51 (1.20 -1.91) for all-cause mortality and 0.92 (0.68 -1.25) 0.93 (0.68 -1.26), and 1.54 (1.14 -2.01) for cardiovascular mortality (Tables 2 and 3 (23) 141 (23) 141 (24) 143 (24) 0.064
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Continued on page 116 malnutrition (albumin and hemoglobin) in our Cox regression analyses did not attenuate the predictive value of SDMA concentrations for total and cardiovascular mortality (data not shown). For ADMA, we observed a gradual increase of allcause and cardiovascular mortality across quartiles. After adjustments for cardiovascular risk factors, the HRs (95% CIs) in the second, third, and fourth quartiles compared to patients in the lowest ADMA quartile were 1.05 (0.83-1.32), 1.19 (0.95-1.50), and 1.61 (1.30 -1.99) for all-cause mortality and 1.00 (0.74 -1.34), 1.26 (0.95-1.68), and 1.54 (1.18 -2.02) for cardiovascular mortality (Tables 2 and 3 ; Fig. 1, B and D Parathyroid hormone (PTH), a predictor of cardiovascular mortality (25 ) that has previously been associated with ADMA concentrations (26 ), was significantly associated with SDMA (r ϭ 0.34, P Ͻ 0.001) and ADMA (r ϭ 0.18, P Ͻ 0.001). Inclusion of PTH as a covariate in our Cox regression analyses, however, did not significantly alter our results (data not shown).
To evaluate whether the association of SDMA or ADMA with mortality might be different in heart failure patients (NYHA 3 or NYHA 4) compared with the remaining study cohort, we tested for interactions by adding product terms of heart failure (yes/no) and ADMA or SDMA concentrations to our Cox proportional hazard analyses. We found no significant interaction indicating that the association of ADMA as well as SDMA with mortality is not significantly different in patients with heart failure vs those without. Reanalyzing our data by use of a CAD definition with a stenosis cutoff Ն50% gave similar results to those using the CAD Ն20% definition.
To quantitatively assess the discriminative predictive power of ADMA and SDMA for mortality, we calculated the C statistic (equivalent to the area under the ROC curve) as described (25, 27 ) . We calculated this C statistic for all-cause mortality according to the multivariate adjusted model (model 3) with and without ADMA as well as SDMA. Parameters from model 3 (age, sex, CAD on angiography, body mass index, hypertension, smoking status, LDL cholesterol, HDL cholesterol, triglycerides, and eGFR) showed discrimination for all-cause mortality of 0.728 (95% CI 0.707-0.748) area under the curve (AUC). Addition of ADMA to the model modified AUC to 0.739 (0.719 -0.754). Removal of ADMA and addition of SDMA changed the 
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139 (14) 139 (14) 139 (15) 137 ( AUC to 0.753 (0.733-0.772). Hence, there is no significant difference between ADMA and SDMA in improving mortality risk prediction, although results for SDMA were tentatively better. Similar results for the C statistic were obtained for cardiovascular mortality (data not shown).
Discussion
The key findings of the largest clinical study so far measuring SDMA and ADMA in patients who underwent coronary angiography confirm that SDMA correlates with parameters of renal function and document that it is independently associated with all-cause and cardiovascular mortality. The prediction is quantitatively different from that provided by ADMA. Our univariate analyses of SDMA and different markers of renal function confirm earlier studies. The consistent increase in mortality with increasing ADMA concentrations in our present analysis is in line with results from other studies (5, 6 ) and confirms our previous LURIC study results with a shorter follow-up (7 ). In contrast to ADMA, the association of SDMA and mortality was J-shaped, with the highest mortality risk for patients in the fourth SDMA quartile and a decreased risk of death in the second compared to the first SDMA quartile. Interestingly, the J-shaped association of SDMA and mortality increased upon multivariable adjustment with cardiovascular risk factors (see model 3, Table 2 ). Furthermore, if we related ADMA to SDMA by multiplication, the rank order of the quartiles in total mortality was also significantly reduced in the second compared to the first quartile (data not shown). Given the observed role of SDMA as a cardiovascular risk factor, we believe that further studies are needed to confirm and extend our findings regarding SDMA and elucidate the underlying mechanisms for the differences of the relationship of ADMA and SDMA with mortality and fatal cardiovascular events. In this context, it may be of interest that increased plasma SDMA concentrations correlated better with the total sequential organ failure assessment than ADMA (33 ) . If our finding is confirmed by independent studies, the measurement of SDMA may emerge as a diagnostic tool for assessment of adverse cardiovascular outcome.
What are the possible pathophysiological mechanisms linking SDMA and mortality? In part, this association can be explained by the fact that SDMA is excreted by glomerular filtration. This strong association of SDMA with eGFR might also partially explain the J-shaped SDMA mortality curve when considering that eGFR shows a U-shaped association with mortality. Toward this, the linear association between renal function and mortality is well documented for eGFR levels Ͻ60 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 (34 ) . In Ͼ33 000 patients, however, it was shown that compared to eGFRs of 60 -90 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 there was a 29% and 163% increase in mortality for patients with eGFRs of 90 -119 and 120 -150 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 , respectively (35 ) . Hence, the SDMA mortality association in our cohort may reflect the association of renal function and mortality. The much weaker association of ADMA with eGFR might be responsible for the differences in the mortality risk prediction by ADMA and SDMA. SDMA, however, retained its predictive power in multivariate analyses, including eGFR or cystatin C, suggesting that mortality prediction by SDMA is not driven only by its association with parameters of renal function. There is experimental evidence that SDMA may indirectly interfere with NO synthesis. SDMA inhibits the yϩ transporter that mediates the intracellular uptake of L-arginine (36 ) and decreases renal tubular arginine absorption (37 ) . These 2 mechanisms could indirectly inhibit NO synthesis by interfering with L-arginine availability. Indeed, in vitro studies using endothelial cells showed that SDMA dosedependently inhibited NO synthesis. This effect was associated with an increase in reactive oxygen species, whereas SDMA had no effect on protein expression of NO synthase (11 ).
Another important mechanism helping to explain the predictive power of SDMA for cardiovascular events is the link between SDMA and inflammation. SDMA is synthesized by protein methyltransferase (PRMT) 7 and PRMT 5 (both type II methyltransferases), which also produce small amounts of ADMA (38, 39 ) It was recently shown that PRMT 5 regulates interleukin-2 gene expression (39 ), a finding that points to a link between SDMA generation and inflammation. In keeping with this hypothesis, Zoccali et al. (40 ) found that SDMA tends to be higher in states of acute inflammation and decreases if inflammation and fever resolve. Moreover, Caglar et al. (41 ) found in patients with proteinuria that high SDMA concentrations are associated with high CRP concentrations. This goes along with our finding that patients with CRP concentrations Ͼ10 mg/L had significantly higher SDMA concentrations than patients with CRP concentrations between 3 and 10 mg/L (data not shown).
Another possible explanation for the predictive power of SDMA in terms of mortality is the fact that SDMA is increased in states of high protein turnover (41, 42 ) . Protein catabolism as part of the metabolic syndrome is associated with increased mortality, and this could help to explain the predictive power of SDMA. Recently it was found that SDMA also stimulates production of reactive oxygen species in monocytes by acting on Ca 2ϩ entry via store-operated Ca 2ϩ channels (43 ) . This proinflammatory effect, together with the indirect effects of SDMA on NO synthesis, and the relationship of SDMA to renal function are thought to be possible mechanisms by which SDMA and cardiovascular disease may be linked. Many longitudinal studies looking at the predictive power of ADMA as a marker of cardiovascular mortality did not report any data on SDMA (6, 44, 45 ) . The seminal study by Zoccali et al. (5 ) showed that in dialysis patients ADMA is a strong predictor of mortality, whereas SDMA has no prognostic value. This comes as no surprise, however, because both creatinine and SDMA rise exponentially with decreasing renal function (chronic kidney disease stage 5), resulting in marked changes in these parameters caused by minute changes in GFR. Our study, however, excluded dialysis patients and patients with advanced impairment of kidney function and concerned patients without primary kidney disease. Apart from this, both SDMA and ADMA have been associated with PTH, which is also associated with poor outcomes and whose relationship with ADMA and SDMA deserves further in-depth studies (25, 26 ) . Finally, we want to note that our present results confirm recently published data indicating that SDMA is a marker of increased risk for cardiovascular disease and mortality (12-16 ) .
We wish to point out 2 crucial limitations of our study. It was not designed to elucidate the pathophysiological pathways linking SDMA to survival, but addressed the potential clinical value of SDMA as a predictor of survival in patients with cardiovascular disease. The design of our study precludes conclusions on cause and effect. Moreover, we did not use methods measuring true glomerular filtration, which would not have been feasible in such a large number of patients. Above all, as pointed out by Manolio (46 ) there are problems inherent to new biomarkers. Although initial reports about novel markers provide exciting clues into the pathophysiology of diseases and enable us to improve diagnostic capabilities, translating these into clinical application requires replication in multiple settings, ideally with an intervention trial proving that modification of the new marker improves outcome. The time-consuming measurement of SDMA by HPLC might be the least problematic component in employing this new marker for routine clinical use.
In summary, this is the first clinical study showing that SDMA is a predictor of survival in patients referred for coronary angiography but with a different impact than its structural isomer ADMA. Future studies should measure and report both methylarginines, i.e., ADMA and SDMA, as both may be independently predictive.
